Article Text

Download PDFPDF
328 RENI-1: a prospective, multicenter real-world study of niraparib as first-line maintenance therapy in newly diagnosed advanced ovarian cancer
  1. Jing Zuo1,
  2. Ke Wang2,
  3. Zhumei Cui3,
  4. Qingshui Li4,
  5. Xiaodong Cheng5,
  6. Zhong Zheng6,
  7. Lixin Sun7,
  8. Hui Zhang8,
  9. Jun Zhang8,
  10. Shuhe Wang9,
  11. Dongyan Cao10,
  12. Lihong Chen11,
  13. Hongqin Zhao12,
  14. Wei Duan13,
  15. Min Zheng14,
  16. Huafeng Shou15,
  17. Jin Li6,
  18. Yue Wang16,
  19. Xiaoxiang Chen17 and
  20. Lingying Wu1
  1. 1National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
  2. 2Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
  3. 3The Affiliated Hospital of Qingdao University, Qingdao, China
  4. 4Shandong Cancer Hospital, Jinan, China
  5. 5Women’s Hospital, Zhejiang University School of Medicine, Hangzhou, China
  6. 6Fudan University Shanghai Cancer Center, Shanghai, China
  7. 7Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, China
  8. 8The Fourth Hospital of Hebei Medical University, Shijiazhuang, China
  9. 9The Seventh Medical Center, Chinese People’s Liberation Army (PLA) General Hospital, Beijing, China
  10. 10Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
  11. 11Shaanxi Provincial People’s Hospital, Shaanxi, China
  12. 12The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
  13. 13Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, China
  14. 14Sun Yat-sen University Cancer Center, Guangzhou, China
  15. 15Zhejiang Provincial People’s Hospital, Hangzhou, China
  16. 16Henan Provincial People’s Hospital, Zhengzhou, China
  17. 17The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, China


Introduction/Background Niraparib is the first PARP inhibitor to be approved for the first-line maintenance (1LM) treatment of all patients with newly diagnosed advanced ovarian cancer. The RENI-1 study (NCT04986371) was designed to evaluate the maintenance treatment patterns, efficacy and safety in ovarian cancer patients who received niraparib as 1LM therapy in the real world.

Methodology The study prospectively enrolled patients eligible for niraparib 1LM therapy. The primary endpoint was the maintenance treatment patterns, including initiation time of maintenance, starting dose of niraparib and maintenance regimens. Secondary endpoints included progression-free survival (PFS), chemotherapy-free interval, time to first subsequent treatment, overall survival, safety and quality of life.

Results From September 2021 to September 2022, 227 per-protocol patients were enrolled in 22 hospitals in China. Of the 227 patients, 210 (92.5%) had III-IV disease, 97 (42.7%) received neoadjuvant chemotherapy, 160 (70.5%) had a complete response to platinum-based chemotherapy, 47 (20.7%) carried BRCA mutations (BRCAm), and 116 (51.1%) had homologous recombination deficiency (HRD). The median initiation time of maintenance was 7.6 weeks (range, 0.9–40 weeks), with 215 (94.7%) patients starting with 200 mg of niraparib and 218 (96.0%) patients receiving niraparib monotherapy. After a median follow-up of 16.8 months, median PFS (mPFS) was 24.2 months and 12-month PFS rate was 70.0% in the overall population. PFS benefit was observed regardless of BRCAm status and HRD status (table 1). Adverse events (AEs) of any grade were reported in 67.4% of patients, including 13.7% grade 3 or higher. AEs led to treatment interruption, dose reduction and discontinuation were 24.2%, 20.3% and 4.0%, respectively.

Conclusion Treatment patterns of niraparib 1LM are diverse in the real world, with BRCAm and HRD patients benefiting the most. The results of this prospective real-world study provide reassuring evidence of the activity and tolerability of niraparib maintenance therapy in newly diagnosed advanced ovarian cancer.

Disclosures All authors have declared no conflicts of interest.

Abstract 328 Table 1

Summary of median PFS, PFS6 and PFS12 by biomarker subgroup

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.